Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Authors:
- Chiaki SaitaCSChiaki Saita
- Risa GotoRGRisa Goto
- Tomoyuki ArugaTATomoyuki Aruga
- Nami IderaNINami Idera
- Yayoi HondaYHYayoi Honda
- Kazumi HoriguchiKHKazumi Horiguchi
- Hiromi MiyamotoHMHiromi Miyamoto
- Shinichiro HoriguchiSHShinichiro Horiguchi
- Toshinari YamashitaTYToshinari Yamashita
- Katsumasa KuroiKKKatsumasa Kuroi
Open Access
- 26 January 2016
- journal article
- case report
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 46
Abstract
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.Keywords
This publication has 8 references indexed in Scilit:
- Papillary and neuroendocrine breast lesions: the WHO stanceHistopathology, 2014
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerBritish Journal of Cancer, 2013
- Clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast: a large case studyJournal of Cancer Research and Clinical Oncology, 2012
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancerCancer, 2007
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18Journal of the National Cancer Institute Monographs, 2001
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001